Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Chinese Subjects With Moderately to Severely Active Crohn's Disease
NCT05837897Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jun 2023
- Primary completion
- Mar 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Jun 2023; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05837897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837897.